PGAM5 and Parkinson disease: Third, most disease duration of our patients was ≤5 years (69%), and the proportion of patients in medium and advanced stages was relatively low, and this may limit further analysis on the relationship between plasma PGAM5 levels and the severity of motor or non-motor manifestations of PD.